TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22155172
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg rifaximin-EIR, given twice daily for 12 weeks
Study: 22155172
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg rifaximin-EIR, given twice daily for 12 weeks
Study: 16288372
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of IPV
Study: 10609245
Drug: Intraoperative injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative injection of epinephrine 1:25,000 in the anterior chamber
Study: 7718375
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose isoflurane
Study: 2248029
Drug: tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiaprofenic acid 300 mg, twice a day for seven consecutive days
Study: 2248029
Drug: placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, twice a day for seven consecutive days
Study: 7221983
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (7 mg)
Study: 7221983
Drug: Mustine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mustine (20 mg)
Study: 29688123
Drug: Early endovenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early endovenous ablation of superficial venous reflux with compression therapy
Study: 29688123
Drug: Deferred endovenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred endovenous ablation of superficial venous reflux with compression therapy
Study: 28351379
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1 mg/kg) for 3 days
Study: 28351379
Drug: Partial endodontic
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial endodontic treatment
Study: 25581605
Drug: Routine incontinence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine incontinence care plus the suspension positioning system (SPS)
Study: 21110172
Drug: Composite sophora
Normalized name: Sophora pachycarpa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite sophora colon-soluble capsules (CSCC) high dose (six capsules, thrice a day)
Study: 21110172
Drug: Composite sophora
Normalized name: Sophora pachycarpa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite sophora colon-soluble capsules (CSCC) low dose (four capsules, thrice a day)
Study: 21110172
Drug: Mesalazine Enteric-coated
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine Enteric-coated Tablets (four tablets, thrice a day)
Study: 21110172
Drug: Composite sophora
Normalized name: Sophora pachycarpa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite sophora colon-soluble capsules (CSCC) high dose
Study: 21110172
Drug: Composite sophora
Normalized name: Sophora pachycarpa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite sophora colon-soluble capsules (CSCC) low dose
Study: 21110172
Drug: Mesalazine Enteric-coated
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine Enteric-coated Tablets
Study: 11965231
Drug: Radioimmunoconjugates emitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioimmunoconjugates emitting beta-particles (e.g., 131I-anti-CD33, 90Y-anti-CD33, 131I-anti-CD45, 188Re-anti-CD66c)
Study: 11965231
Drug: Radioimmunoconjugates emitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioimmunoconjugates emitting alpha-particles (e.g., 213Bi-anti-CD33)
Study: 11965231
Drug: Radiolabeled antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabeled antibodies
Study: 11965231
Drug: Radiolabeled antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabeled antibodies used in conjunction with conditioning regimens
Study: 2679680
Drug: sulbactam/ampicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulbactam/ampicillin (1 g:2 g) administered intravenously every 8 h
Study: 2679680
Drug: cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefotetan (2 g) administered intravenously every 12 h
Study: 19548446
Drug: Shuxuetong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuetong Injection (SXT)
Study: 428840
Drug: Actihaemyl (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actihaemyl (6 weeks, twice weekly 10 ml i.v.)
Study: 30741761
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy alone (Control)
Study: 30741761
Drug: Ergonomic latex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergonomic latex pillow with physical therapy
Study: 9862576
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg m(‐2) on day 1 (112 patients)
Study: 9862576
Drug: Epirubicin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 150 mg m(‐2) on day 1 (111 patients)
Study: 9862576
Drug: Epirubicin 50
Normalized name: epiRUBicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 50 mg m(‐2) on days 1, 2, and 3 (111 patients)
Study: 7623523
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) at low doses (30 mg and 100 mg)
Study: 7623523
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) at moderate doses (400 mg)
Study: 67128
Drug: Rectal oxymorphone
Normalized name: oxymorphone hydrochloride Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal oxymorphone
Study: 26253566
Drug: Initial dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dual therapy (combination therapy)
Study: 22103436
Drug: Initial monotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial monotherapy
Study: 16879829
Drug: 1.35 g
Normalized name: Octinoxate 1.35 g in 30 g TOPICAL CREAM [LBel Supremacie Teint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.35 g EPA/day
Study: 16879829
Drug: 2.7 g
Normalized name: Magnesium 420 MG/2.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 g EPA/day
Study: 16879829
Drug: 4.05 g
Normalized name: ZINC OXIDE 24.05 g in 100 g TOPICAL CREAM [Hi papa KIDS MINERAL FACE SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.05 g EPA/day
Study: 16879829
Drug: EPA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (all doses)
Study: 16879829
Drug: Highest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest dose of EPA
Study: 16879829
Drug: Increased EPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased EPA (all doses)
Study: 11386610
Drug: Single 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 10‐mg dose of diazepam
Study: 11386610
Drug: Drug abusers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug abusers starting a prison sentence
Study: 9739972
Drug: Oral famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral famciclovir (125 mg or 250 mg 3 times daily or 250 mg twice daily)
Study: 2522371
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose containing 10 U l‐1 insulin
Study: 2522371
Drug: 10% glucose
Normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glucose with 40 U l‐1 insulin
Study: 8679756
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg)
Study: 5792911
Drug: Saline (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% solution, 10 ml)
Study: 26693643
Drug: Milk-based liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based liquid meal supplement (Sustagen Sport)
Study: 25547902
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/d orally, intermittent administration on days 2 to 16 every 21 days, combined with docetaxel 75 mg/m² every 21 days
Study: 25547902
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/d orally, administered continuously
Study: 12580986
Drug: Gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MR (30 mg initial dose)
Study: 7159686
Drug: Sustained-release quinidine
Normalized name: quinidine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release quinidine tablet (300 mg)
Study: 7159686
Drug: Oral quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinidine sulfate solution (300 mg)
Study: 29726951
Drug: Walnut consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut consumption (42 g walnuts/d)
Study: 25536669
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 3 mg daily
Study: 25536669
Drug: rosiglitazone (Rosi)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rosiglitazone (Rosi) 4 mg twice daily
Study: 25536669
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rhGH and Rosi
Study: 23582949
Drug: Intermittent Hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent Hormonal Therapy (IHT) with cyproterone acetate (CPA) 200 mg/d for 2 weeks, then monthly LHRH analogue plus CPA 200 mg/d.
Study: 23582949
Drug: Continuous Maximal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Maximal Androgen Blockade (MAB) with CPA 200 mg/d plus monthly LHRH analogue.
Study: 24009704
Drug: Mindfulness based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness based cognitive therapy (MBCT)
Study: 18698881
Drug: Slow-escalation treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Slow-escalation treprostinil dosing regimen
Study: 18698881
Drug: Rapid-escalation treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rapid-escalation treprostinil dosing regimen
Study: 16538016
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia maintained with 2 L of oxygen, 4 L of nitrous oxide, and 1% to 3% isoflurane
Study: 12824786
Drug: GM‐CSF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF (300 microg by subcutaneous injection three times weekly for 4 weeks)
Study: 10632688
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
Study: 10632688
Drug: ELA-Max cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELA-Max cream (lidocaine 4%)
Study: 10632688
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (EMLA and ELA-Max combined)
Study: 8389667
Drug: Ifosfamide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 2.0 g/m2 days 1 to 3 with cisplatin 33 mg/m2 days 1 to 3
Study: 8389667
Drug: Ifosfamide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 2.5 g/m2 days 1 to 3 with cisplatin 33 mg/m2 days 1 to 3
Study: 8389667
Drug: Ifosfamide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 2.0 g/m2 days 1 to 3
Study: 8389667
Drug: Ifosfamide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 2.5 g/m2 days 1 to 3
Study: 3555033
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin plus azlocillin
Study: 6151842
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of temazepam
Study: 6138061
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of flurazepam
Study: 28929925
Drug: Participant-directed occupational
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant-directed occupational therapy intervention
Study: 15961761
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m(2) plus ifosfamide 5 g/m(2) during 24 hours and cisplatin 75 mg/m(2) every 3 weeks for three courses (TIP)
Study: 15961761
Drug: Ifosfamide 5
Normalized name: ifosfamide 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 5 g/m(2) during 24 hours plus cisplatin 75 mg/m(2) (IP)
Study: 11992097
Drug: PNU-83757 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-83757 (10 mcg, 60-140 mcg)
Study: 19686479
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia (TIVA)
Study: 22169620
Drug: Menaquinone-7 (vitamin
Normalized name: menaquinone-7 (vitamin K2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-7 (vitamin K(2)) treatment at 45, 135, or 360 μg/d for 6 weeks
Study: 18236186
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ibandronate (1 mL) applied to the tibial bone surface 1 min before cementation
Study: 18236186
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL saline applied to the tibial bone surface 1 min before cementation
Study: 8586527
Drug: i.v. essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. essential amino acids (EAA) solution 13.4 g daily + dopamine i.v. 2 micrograms/kg/min + 20% hypertonic glucose solution 500 ml/d
Study: 8586527
Drug: dopamine i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: dopamine i.v. 2 micrograms/kg/min + 20% hypertonic glucose solution 500 ml/d
Study: 2527048
Drug: glutamyl-L-dopa (gludopa)
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glutamyl-L-dopa (gludopa)
Study: 782685
Drug: Extended maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended maintenance CO treatment
Study: 31104005
Drug: Mulligan's mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulligan's mobilization with movement (MWM), exercise, and cold therapy
Study: 21665501
Drug: 5% povidone-iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% povidone-iodine preparation with no regard to eyebrows (Group A)
Study: 21665501
Drug: 5% povidone-iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% povidone-iodine preparation with eyebrows excluded (Group B)
Study: 21665501
Drug: 5% povidone-iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% povidone-iodine preparation with bladed lid speculum (Group C)
Study: 21665501
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as standard preparation)
Study: 16935870
Drug: Azimilide (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide (125 mg o.d.)
Study: 16935870
Drug: Sotalol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (160 mg b.i.d.)
Study: 15342288
Drug: Immediate-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release niacin (3,000 mg/day)
Study: 15342288
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (1,500 mg/day)
Study: 8395712
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparins (LMWH) administered subcutaneously
Study: 8395712
Drug: Outpatient LMWH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient LMWH therapy
Study: 2868659
Drug: Alpha blocker
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha blocker (prazosin)
Study: 6143471
Drug: Diuretic (hydrochlorothiazide)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic (hydrochlorothiazide)
Study: 2201721
Drug: Zopiclone 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 15 mg
Study: 12698315
Drug: Water (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (750 ml)
Study: 12698315
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (750 ml)
Study: 8736053
Drug: Rhinomer (cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinomer (cleansing preparation of isotonic, sterile, undiluted sea water)
Study: 8736053
Drug: Prorhinel (marketed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prorhinel (marketed solution containing an antiseptic agent)
Study: 26026580
Drug: Ramelteon (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (8 mg nightly for 3 weeks)
Study: 25227477
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy during labor
Study: 21103989
Drug: 35-g/m2 titanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35-g/m2 titanized polypropylene mesh (Group A)
Study: 21103989
Drug: 16-g/m2 titanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-g/m2 titanized polypropylene mesh (Group B)
Study: 18612886
Drug: Younger age
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger age and history of outpatient psychological treatment
Study: 15820760
Drug: O-[11C]methyl-L-tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-[11C]methyl-L-tyrosine
Study: 2128094
Drug: Phentolamine (1-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (1-1.5 mg/min)
Study: 30808625
Drug: golimumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab (50 mg SC monthly) + MTX (n=26)
Study: 25424398
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) - 16 weekly sessions
Study: 18440534
Drug: Metformin (1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1700 mg/day for 6 months)
Study: 18440534
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) (50 mg/day, increasing doses up to 250 mg/day)
Study: 17366011
Drug: Ampicillin-sulbactam 18/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam 18/9 g daily dose (group A)
Study: 17366011
Drug: Ampicillin-sulbactam 24/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam 24/12 g daily dose (group B)
Study: 2906477
Drug: Olsalazine, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine, 500 mg b.d.
Study: 2906477
Drug: Sulphasalazine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine, 1 g b.d.
Study: 29685343
Drug: Cabazitaxel Q1W,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel Q1W, 10 mg/m2
Study: 29685343
Drug: Cabazitaxel Q3W,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel Q3W, 25 mg/m2
Study: 28093636
Drug: No shock
Approvals — FDA: no, EMA: no, PMDA: no
Description: No shock wave therapy (control group)
Study: 11214014
Drug: Allopurinol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (1 g)
Study: 1558834
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/day for 10 days)
Study: 3911365
Drug: Antacid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid group (4 chewable aluminum-magnesium-antacid tablets daily)
Study: 3911365
Drug: Antacid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid group
Study: 31944472
Drug: 18-month weight
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18-month weight management intervention (reduced calorie diet, 150 min of moderate-vigorous intensity physical activity per week, daily dietary logging, monthly at-home visits by a health educator)
Study: 23258136
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride (10 µg/kg/min, continuous intravenous)
Study: 18501909
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg intravenous dose
Study: 15987918
Drug: Oral capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine (1004 patients)
Study: 14525817
Drug: Ropivacaine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 60 mg
Study: 14525817
Drug: Midazolam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.03 mg/kg prior to ropivacaine
Study: 8808721
Drug: Ifosfamide 5
Normalized name: ifosfamide 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 5 g/m2xdx1 and doxorubicin 60 mg/m2xdx1 given every 3 weeks with r‐met Hu G‐CSF (250 micrograms/m2xd)
Study: 8808721
Drug: Ifosfamide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 1.8 g/m2xdx5 and doxorubicin 60 mg/m2xdx1 given every 4 weeks
Study: 1419009
Drug: IM ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM ketorolac 30 mg while in the PACU, followed by 15 mg every 6 hours
Study: 1419009
Drug: IM ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM ketorolac 60 mg while in the PACU, followed by 30 mg every 6 hours
Study: 1419009
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA morphine
Study: 30721941
Drug: Lipid-based micronutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based micronutrient supplement commenced ≥3 months before conception (Arm 1)
Study: 30721941
Drug: Lipid-based micronutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based micronutrient supplement commenced late in the first trimester of pregnancy (Arm 2)